Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics Inc | RCV000517408 | SCV000614043 | uncertain significance | not specified | 2016-11-09 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001726210 | SCV001961700 | uncertain significance | not provided | 2021-07-01 | criteria provided, single submitter | clinical testing | |
Invitae | RCV002525052 | SCV003255889 | uncertain significance | Frontotemporal dementia | 2022-07-01 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 107 of the MAPT protein (p.Gly107Val). This variant is present in population databases (rs144397565, gnomAD 0.003%). This missense change has been observed in individual(s) with MAPT-related conditions (PMID: 27776828). ClinVar contains an entry for this variant (Variation ID: 447706). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |